References
- Davis ME. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7:771–82
- Ferrari M. (2010). Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol 28:181–8
- Geissmann F, Gordon S, Hume DA, et al. (2010). Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 10:453–60
- Gordon AN, Fleagle JT, Guthrie D, et al. (2001). Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312–22
- Jain RK, Stylianopoulos T. (2010). Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7:653–64
- Kojic M, Filipovic N, Slavkovic R, et al. (1998, 2009). PAK-FS – finite element program for fluid flow and fluid-solid interaction. Kragujevac: University of Kragujevac and R&D Center for Bioengineering
- Kojic M, Filipovic N, Stojanovic B, et al. (2008). Computer modeling in bioengineering: theoretical background, examples and software. Chichester, England, John Wiley and Sons. pp 131–156
- Kojic M, Milosevic M, Kojic N, et al. (2011a). On diffusion in nanospace. J Serbian Soc Comput Mech 5:104–18
- Kojic M, Ziemys A, Milosevic M, et al. (2011b). Transport in biological systems. J Serbian Soc Comput Mech 5:101–28
- Kojic M, Milosevic M, Kojic N, et al. (2014). A multiscale MD-FE model of diffusion in composite media with internal surface interaction based on numerical homogenization procedure. Comput Methods Appl Mech Eng 269:123–38
- Maeda H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189–207
- Maeda H, Wu J, Sawa T, et al. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–84
- McVie JG. (1984). The role of pharmacokinetics in (combination) chemotherapy. Cancer 54:1175–8
- Müller M, dela Peña A, Derendorf H. (2004). Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother 48:1441–53
- Norvaisas P, Ziemys A. (2014). The role of payload hydrophobicity in nanotherapeutic pharmacokinetics. J Pharm Sci 103:2147–56
- Nugent LJ, Jain RK. (1984). Extravascular diffusion in normal and neoplastic tissues. Cancer Res 44:238–44
- O'Brien M, Wigler N, Inbar M, et al. (2004). CAELYX Breast Cancer Study Group: reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440–9
- Park K. (2013). Facing the truth about nanotechnology in drug delivery. ACS Nano 7:7442–7
- Presant C, Wolf W, Waluch V, et al. (1994). Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet 343:1184–7
- Simovic S, Prestidge CA. (2007). Nanoparticle layers controlling drug release from emulsions. Eur J Pharm Biopharm 67:39–47
- Singhal S, Henderson R, Horsfield K, et al. (1973). Morphometry of the human pulmonary arterial tree. Circ Res 33:190–7
- Vaupel P, Kallinowski F, Okunieff P. (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49:6449–65
- Wacker MG. (2014). Nanotherapeutics – product development along the “nanomaterial” discussion. J Pharm Sci 103:777–84
- Wolf W, Presant CA. (2004). Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics. Clin Pharmacol Ther 76:508–8
- Yokoi K, Kojic M, Milosevic M, et al. (2014). Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment. Cancer Res 74:4239–46
- Ziemys A, Kojic M, Milosevic M, et al. (2011). Hierarchical modeling of diffusive transport through nanochannels by coupling molecular dynamics with finite element method. J Comput Phys 230:5722–31